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Anti-depressant therapy is one of the most common treatments for depression. However, the 
increasing criticism regarding anti-depressant therapy and increased suicidality has caused both 
health care providers and the public to question their widespread use (Lader, 2007). In October 
2004, the Food and Drug Administration (FDA) mandated that a black box warning be added to 
anti-depressant medications in order to alert patients of increased risk of suicidal thoughts in the 
pediatric and adolescent population. This black box warning was expanded further to include 
patients between 18 to 24 years-of-age at the direction of the FDA in May of 2007 (Friedman & 
Leon, 2007). It has been noted that a common reason patients do not report their symptoms of 
depression is due to fear that the physician will recommend an anti-depressant (Bell et al., 2011). 
Every year in the United States (U.S.), 30,000 people die of suicide and an additional 650,000 
people are treated in emergency departments after attempting suicide (Schreiber, Culpepper, & 
Fife, 2012), making it imperative to investigate the link between anti-depressants and suicidality. 
Studies which focused on the correlation between anti-depressant therapy and suicidality as well 
as studies that looked at additional factors (i.e. genetics, toxicological findings) that could have a 
strong impact on suicidality were reviewed. The findings of this project indicate that, in studies 
examining whether there is a correlation between anti-depressant therapy and suicidality, there 
are too many unknown factors to determine whether anti-depressant therapy is the lone factor 
responsible for the development of suicidality in patients. Additionally, there is a great need for 
research, particularly in the areas of genetics and toxicology, in order to determine whether these 
factors play a role in the development of suicidality.
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Research Based Findings of Anti-depressant Therapy and Suicidality
The Centers for Disease Control and Prevention (CDC) define depression as an affective 
disorder characterized by at least five of the following symptoms for a period of two or more 
weeks: depressed or sad mood, diminished interest in activities which used to be pleasurable, 
weight gain or loss, psychomotor agitation or retardation, fatigue, inappropriate guilt, difficulties 
concentrating, or recurrent thoughts of death. Depression not only affects the way an individual 
feels, but can also have profound effects on an individual’s relationships as well as work and/or 
school performance (CDC, 2011). In fact, depression is currently the number one cause of
disability and missed work in the U.S. (Cancro, 2011) and is also one of the most common 
reasons for suicide (Reeves & Ladner, 2010). It is estimated that approximately 20 percent of 
women and 12 percent of men in the United States (U.S.) will experience depression during their 
lifetime (Porth & Matfin, 2009). Of those who encounter one episode of depression, about 50 
percent will experience subsequent episodes of depression (CDC, 2011).
With mental health drawing more attention in both the medical world and the public eye, 
much emphasis has been placed on finding the best methods to treat depression. While many 
studies have found anti-depressant therapy to be efficacious, the possibility of suicide as an
unfortunate outcome resulting from antidepressant therapy leaves many feeling apprehensive 
about their use. Determining whether anti-depressant medications increase the risk of suicidality 
has proven both controversial and contradictory. Meanwhile, the emphasis on anti-depressant 
associated suicidality may have overshadowed the decrease in the rates of suicide attempts and 
completions that have also been associated with anti-depressant therapy. Furthermore, other 
factors, such as a history of suicidal ideation or behavior prior to beginning an anti-depressant, 
co-morbid psychiatric disorders, and/or substance abuse issues may increase the likelihood of
suicidal ideation while taking anti-depressant medications, but may not be at all related to the 
anti-depressant therapy. The objective of this project was to review literature related to anti­
depressant therapy and suicidality (including suicidal ideation, suicidal attempts, and suicide 
completions) to investigate whether or not treating patients with anti-depressants is linked to 
increased or decreased rates of suicidal ideation and/or suicidal behavior. These studies were 
also reviewed to determine whether or not other confounding factors that may contribute to 
suicidality were considered in the study results. Studies that may support a need for additional 
research in regards to anti-depressants and suicidality (i.e. toxicological levels and genetic 
factors) were also reviewed.
Purpose
Suicide is a tragic and unfortunate outcome for patients struggling with psychiatric 
illness...it is “the ultimate endpoint” (Dolgin, 2012, p. 190). The psychiatric illnesses associated 
with the highest risk of suicide are: depression, anxiety disorders (including panic disorder and 
post-traumatic stress disorder), alcoholism, substance abuse, bipolar disorder, schizophrenia, 
personality disorders, and delirium (Schreiber, Culpepper, & Fife, 2012). Additionally, a prior 
and/or psychiatric hospitalization significantly increases the risk for suicide 
ct, prior history of suicide attempts have been identified as the strongest 
single predictor of future suicide attempts (Olmer, Iancu, & Strous, 2009).
In addition to personality characteristics or co-morbid mental illnesses associated with
also measureable demographic factors that increase the risk of suicide. Men 
are four times as likely as women to die of suicide. Suicide rates in those aged 65 years and 
older occurred at a rate of 14.3 per 100,000 people, versus the 11.3 suicides per 100,000 people 
of all ages. Suicide rates of non-Hispanic white men aged 85 years and older occurred at a rate
history of self-harm 
(Lader, 2007). In fa
suicidality, there are
6
of 47 per 100,000 pbople (NIMN, 2012). From this data, one could surmise that in order for 
research studies to properly analyze the link between suicide and anti-depressant therapy with 
that of the general population, the study should include four times as many men as women, and 
should also include men over the age of 65 years and 85 years-of-age. The methods that studies 
use to depict the agds of the participant population (which are often as a mean with a standard 
deviation) make it difficult to determine the exact demographics of the study population.
Studies have shown that the initiation of anti-depressants reduced suicidal thoughts or 
behavior in patients who were previously experiencing suicidal thoughts (Simon, 2012). 
However, warnings that there may be a direct correlation between anti-depressant use and 
suicidality have left some medical professionals and patients skeptical about their safety (Lader, 
2007). This skepticism can lead to the under-diagnosis and under-treatment of psychiatric 
illness, which is adVerse to positive patient care and outcomes.
The facts regarding untreated psychiatric illness and suicide seem to be obscured as the 
controversy over the correlation between anti-depressant use and suicidality continues to swirl. 
For example, one observational study performed over a 38 year period found that 14 percent of 
the participants committed suicide. This suicide rate is an astounding 27 times greater than that 
of the general population (Simon, 2012). In order to provide for the best interests of the patient, 
it is important to determine whether or not studies that have focused on this correlation have 
considered confounding factors, such as those factors listed as high risk for suicide previously in 
the paper. This project will analyze the outcomes of research studies that focus on the 
correlation between anti-depressant therapy and suicidality to determine if there could be other 
factors which contribute to suicidality in participants who reported experiencing suicidality after 
initiating anti-deprekant therapy.
Significance
Anti-depressants are largely considered an efficacious treatment of depression, anxiety,
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and other mental health disorders. However, the FDA warnings issued in 2004 and 2007 
regarding anti-depressant use and increased suicidality in the pediatric, adolescent, and young 
adult population seems to have decreased the rates of both diagnosing depression and treating 
patients with anti-depressants (Simon, 2012). This is unfortunate because the meta-analysis 
which led to the FDA warning included no completed suicides, infrequent suicide attempts, and 
only found clinical significance related to the correlation between anti-depressants and 
suicidality when suicidal ideation and possible suicidal ideation were added as endpoints in the 
study (Valuck, Orton, & Libby, 2009). The reluctance among some prescribers when 
considering whether or not to use anti-depressants as a treatment is a huge concern (Lader,
2007), especially since studies have found anti-depressant treatment to be associated with 
significantly lower fates of suicidal mortality when compared to untreated depressed patients 
(Simon, 2012).
Suicide is the tenth leading cause of death worldwide (Schreiber, Culpepper, & Fife, 
2012) and the third eading cause of death in people under 45 years-of-age in the U.S. (Dolgin, 
2012). Of those who complete suicide, more than 95 percent have at least one psychiatric 
diagnosis (Schreiber, Culpepper, & Fife, 2012). In order to diagnose and treat patients 
appropriately, it is imperative to clarify the risks involved where anti-depressants and suicidality 
are concerned. However, despite the unknowns related to suicide and anti-depressants, in 2011, 
the National Institutes of Health (NIH) spent only about 0.6 percent of their total budget on 
suicide prevention, and a little more than twice that on suicide research in comparison to the 10% 
of the agency’s budget that was utilized to research HIV/AIDS (Dolgin, 2012).
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Some professionals have suggested that the FDA consider utilizing epidemiologic data as 
a way to determine whether or not medications have the outcomes sought in the general 
population. For example, one psychiatrist petitioned to have the FDA consider 31 observational 
studies showing that lithium “can reduce the risk of suicidal behaviors in individuals with bipolar 
disorder or other major mood disorders by as much as 80 percent” (Dolgin, 2012, p. 192). The 
FDA stated that, in order to consider epidemiologic data, there would need to be “an 
overwhelming amount of observational data” showing that lithium did reduce suicide (Dolgin, p.
192). What the FDA recommended was performing randomized trials that consisted of 5,000 
participants exposed over a time period of two years or more.
The medical field (and the general public) needs accurate information on whether anti­
depressant therapy, in itself, causes suicidality, or whether other confounding factors cause 
suicidality in patients who are being treated with anti-depressants. Finding answers to the 
question of suicidality related to anti-depressants may be difficult, however, due to the rarity of 
suicidal behaviors in clinical trial participants, an inadequate amount of information related to 
people who attempt suicide in the real-world population, and “ethical issues involved in studying 
this severe outcome with randomized, placebo controlled trials,” (Valuck, Orton, & Libby, 2009, 
p. 1069). In fact, drug trials involving psychiatric medications exclude patients experiencing 
suicidal thoughts from their studies due to ethical concerns (Dolgin, 2012). However, despite the 
controversy regarding the correlation between anti-depressants and suicidality and the ethical 
issues that limit research parameters in this area, providers and patients alike have a right to
know the risk factors associated with anti-depressants and what other factors may contribute to 
suicidality so, together, they can make an informed decision about the treatment plan.
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Theoretical Framework
There are many factors that play a part in an individual’s suicidality. While some of these 
factors are easy to determine by reviewing a patient’s medical record (i.e. comorbid medical and 
mental illness, prior history of suicide attempts or psychiatric hospitalizations, or comorbid 
substance abuse), some factors (such as brain derived neurotrophic factor levels or genetics) are 
more difficult to detect. The biopsychosocial theory fits the purpose of this project because there 
are many components that can play a role in the development of suicidality during anti­
depressant treatment, and all factors must be considered while assessing what role, if any, anti­
depressants play in suicidality.
This project includes several studies which emphasize different factors that can play a role 
in the development of suicidality among patients. This is necessary in order to establish an 
understanding that the development of suicidality is multi-factoral. It is not something that can 
be accurately measured by a study which analyzes one specific factor (i.e. genetic factors 
involved in suicidality or a correlation between anti-depressant use and suicidality). Therefore, 
determining whether or not anti-depressant therapy increases the risk for suicidality is difficult 
because there are numerous factors that play a role in this.
By using the biopsychosocial theory to guide this project, the author reviewed studies that 
analyzed the correlation between anti-depressant therapy and suicidality. However, studies that 
analyzed other factors, such as genetics, that may play a role in suicidality were also reviewed. 
Three studies in which serum toxicology levels were tested in individuals who committed suicide 
were reviewed to determine what percentage of these individuals had anti-depressants in their 
system. The only competent way to look at suicidality is to look at the information from a multi­
faceted view. It is difficult to get a broad view of how anti-depressant therapy correlates with
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suicidality when many studies do not take the other multiple possible reasons for suicidality into 
account.
Definitions
There are several key terms pertinent to this project. These terms are defined below. It is 
important for readers to understand the differences between these terms in order to better 
understand how each has been used for the purpose of this project.
■ Depression: An affective disorder characterized by at least five of the following symptoms
for a period of two or more weeks: depressed or sad mood, diminished interest in 
activities which used to be pleasurable, weight gain or loss, psychomotor agitation or 
retardation, fatigue, inappropriate guilt, difficulties concentrating, or recurrent thoughts 
of death (CDC, 2011).
■ Suicidality: A term inclusive of suicidal thoughts, preparatory acts, suicide attempts and
suicide completions
■ Suicide attempt: An act that is carried out with the intention of resulting in one’s own
death
■ Suicide completion: An act that is committed with the intention of, and has resulted in,
one’s own death
■ Suicidal ideation: Thoughts of killing oneself
■ Non Suicidal Self Injury: Self-injurious bodily injury performed to damage the body
surface, but not done as a way to commit suicide. Examples include cutting, burning, or 
hitting oneself (APA, 2012).
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Review of the Literature
Several research studies have attempted to provide answers to the question of whether or 
not there is a correlation between anti-depressant use and suicide and/or suicidal 
thoughts/behaviors. However, study results have proven controversial. Some studies have found 
that anti-depressants do cause suicidal thoughts/behaviors while other studies have found just the 
opposite. Outcomes of other studies have referenced an increase in suicidal thoughts, but a 
decreased rate of both suicidal behavior and mortality due to suicide where anti-depressant 
treatment is utilized.
Observational studies attempting to link antidepressants to suicidality may be skewed 
solely by confounds of indication due to the increased risk in suicide in the population being 
studied (Isacsson, Holmgren, & Ahlner, 2005; Isacsson, Holmgren, & Ahlner, 2009; Cougnard et 
al., 2009), while randomized controlled trials often exclude potential participants experiencing 
suicidal ideation. Furthermore, the short period of follow-up and stringent inclusion and 
exclusion criteria of randomized controlled trials make it difficult to test theories on a population 
of participants similar to the population of patients treated with antidepressants in real world 
conditions. Furthermore, it is often difficult to draw a conclusive theory in regards to the 
outcome of randomized controlled trials, due to the short treatment duration and small number of 
participants in the studies (Cougnard et al., 2009).
In addition to the mental health diagnoses listed previously in the paper as increasing the 
risk for suicidality, studies have also identified an association between genetic factors and 
suicidality. Perroud et al. (2009) found that a genetic polymorphism in the brain derived 
neurotrophic factor (BDNF) gene could also be a strong genetic factor contributing to increased 
suicidality. The authors further noted that several studies have found, “a decreased level of
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BDNF in the hippocampus and prefrontal cortex (PFC) of suicide victims and in the 
cerebrospinal fluid (CSF) and plasma of suicide attempters (Perroud et al. 2009, p. 2523).” In 
addition, Olmer, Iancu, and Strous, (2012) found that, with separate interventions of 
psychotherapy and antidepressant therapy, and a combination of the two interventions, the 
incidence of suicide is highest in the month prior to initiation of treatment and the risk declines 
steadily over the next six months.
Rucci et al. (2011) studied whether 318 participants who were randomly assigned into 
treatment with either the serotonin reuptake inhibitor (SSRI) escitalopram or psychotherapy
nee emergent suicidal ideation (ESI) during the course of a 20 week period 
ollowed. The participants were selected from two University Outpatient 
Clinics (University Of Pittsburg and the outpatient clinic of the Osperdale Santa Chiara of the 
University of Pisa) between April 2003 and April 2008. Of the 318 participants, 210 were 
female and 108 were male. All participants were between 18 and 66 years of age and had a 
diagnosis of a non-psychotic major depressive episode. Ninety participants were experiencing 
depressive illness, while 201 reported having two or more episodes of 
nally, suicidal thoughts were present in 59 of the participants at the time of
(IPT) would experie 
in which they were
their first episode of 
depression. Additio
study are as follows 
general population) 
commonly used inte
pretreatment interview, while one participant noted having a suicide plan. The strengths of this
participants were referred from outpatient clinics (and not based from the 
who were randomized assigned to treatment groups; the outcomes of two 
jrventions for the treatment of major depressive episodes were compared; 
participants experiencing suicidal thoughts at the baseline interview were included in the study. 
The limitations of the study were: a small participant pool (N=318); the participant pool 
consisted of 72 percent females; the mean age was relatively young (38.3 years); the study did
13
not include patient over 64 years old or those under age 19; the study only utilized one 
medication as a therapeutic intervention which limits the results of the study from use in other 
drug populations; patients with psychotic depression, active suicidal ideation with a plan, current 
alcohol or drug abuse, current eating disorders, and newly diagnosed and unstable physical 
illness were excluded from the study.
The findings of this study were interesting because of the 21 participants who had a 
history of previous suicide attempts, none developed ESI during treatment. Of the 231 
participants who were free of any suicidal thoughts at baseline, 32 exhibited ESI at some point 
during the follow-up period. Twenty-two of the participants who developed ESI had been 
assigned to the IPT group, while ten had been assigned to the escitalopram group. Time from 
initiation of treatment to development of ESI was as follows: less than four weeks (N=13); 
between five and eight weeks (N=9); and after eight weeks (N=10). The study also found that 
time to suicidal ideation was significantly longer for those in the SSRI group versus the IPT 
group. Patients who developed ESI during the study were able to be managed successfully by 
the study protocol, and referral to a higher level of care was only required in two cases (Rucci et 
al., 2011).
Mulder, Joyce, & Frampton, (2008) scrutinized whether treating patients, who were 
either currently experiencing suicidal ideation or had a history of suicide attempts with anti­
depressants, reduced those thoughts/behaviors over time. The study focused on 195 patients who 
were referred by psychiatric emergency services, community mental health centers, and general 
practitioners from 1993 to 2001. The inclusion criteria were: at least 18 years of age, primary 
current diagnosis of major depression; willing and able to give informed consent; treatment with 
antidepressants was deemed to be appropriate management. Patients who were breastfeeding,
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pregnant, likely to become pregnant, had a major medical disorder that could complicate 
assessment or treatment, severe drug or alcohol dependence; and a history of mania, 
schizoaffective disorder, or schizophrenia were all exclusionary criteria.
The participants of the above study were 57.4% were female and the mean age was 32.2 
(SD 11.4) years. Most of the patients denied any suicidal ideation, however, 34.6% of 
participants reported at least moderate suicidal ideation. Additionally, 23.3% (39 patients) had 
reported a suicide attempt within six months prior to treatment, while 12 participants reported 
more than one suicide attempt in the previous six months. Participants met DSM-III-R criteria 
for at least one of the following disorders: bipolar II disorder (9%); melancholia (44%); atypical 
depression (8%); recurrent depression (52%); chronic depression (64%) (Mulder, Joyce, & 
Frampton, 2008).
The participants were then randomly assigned to receive a treatment of either fluoxetine 
or nortriptyline. They were interviewed and asked about whether they had experienced suicidal 
4 days. Their answers were rated as none, occasional, moderate, and 
6,9,13, 20, and 26, participants were asked about any suicide attempts since 
the previous visit. After six weeks of treatment, participants continued on their current 
medications if they had responded to it. Those who did not respond to the initial medication 
were switched to the other medication group. If participants did not respond to the second 
medication, the two medications were combined, and subsequently, the clinician was free to use 
whatever medication he/she felt was clinically indicated. The patients were divided into three 
groups based on their treatment outcome; patients who recovered and remained well until the 
six-month assessment; patients who either achieved remission or recovered but subsequently 
relapsed; patients with persistent depression (Mulder, Joyce, & Frampton, 2008).
ideation in the past 
regular. At weeks 3
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Of the 195 participants initiated into the study, 176 remained at the time of the six month 
follow up. Ten participants dropped out.. .nine left the area, and one withdrew without treatment 
and later committed suicide. Sixty-six percent of the patients had continued to take fluoxetine or 
nortriptyline, while 24 patients had either elected to stop the medications or had found it 
intolerable (however they did remain in the study). Throughout the six month course of 
treatment, 29 patients attempted suicide. This is in comparison to the 51 patients who reported 
attempting suicide at least once in the six months prior to the study. The study further found 
that that antidepressant treatment reduced suicidal ideation by 33% in the first three weeks of 
treatment and 38% over the course of six months, and that the number of suicide attempts 
dropped by 50 % in comparison to the six month period prior to treatment. None of the patients 
without suicidal ideation or suicide attempts in the six months prior to treatment who developed 
ESI during the study (N=5) attempted suicide (Mulder, Joyce, & Frampton, 2008).
emuller et al. (2009) performed a prospective naturalistic study that included 
ho were recruited from seven German psychiatric university hospitals. The 
participants were between 18 and 65 years of age, were willing and able to sign informed 
consent, and had a diagnosis meeting criteria for any major depressive episode confirmed using 
the Structured Clinical Interview for DSM-IV. This study analyzed 18 predictors: “HAMD total 
score; gender; age (also dichotomized >45 or over <_45); years since first diagnosis; suicide
before hospitalization; suicide in first and second-degree relatives; alcohol 
; any substance abuse or dependency; any comorbid personality disorder; 
diagnosis of any bipolar disorder; number of hospitalizations; akathisia; presence of childhood 
trauma; treatment resistance; family status; children; native language German” (Seemuller et al. 






severely depressed upon admission. Of the 1,014 study participants, 137 had attempted suicide 
immediately prior to being admitted to the hospital. During treatment, 10 participants attempted 
suicide and two participants completed suicide. The study found that 14.4% of participants 
experienced worsening of suicidal ideation, compared to 90 percent of participants who reported 
improvement in suicidal ideation. The study additionally identified that patients under age 45 
years are more likely to experience ESI. When compared to that general population, suicide 
rates among study participants were much higher; however, these rates were only slightly 
elevated in comparison to those commonly found in RCTs. Furthermore, 22 potential risk 
factors for extended emergence suicidal ideation were determined, but two independent 
statistical methods identified age, treatment resistance, number of hospitalizations, presence of 
akathisia, and comorbid personality disorder.
Olmer, Iancu, and Strous (2012) performed a retrospective study in which they reviewed 
adult patients admitted to the Beer Yaakov Mental Health Center from 2000 to 2007 with a 
diagnosis of major depressive disorder (MDD). The aim of the study was to analyze whether 
antidepressants have a significant relationship in suicide attempts. Upon review of the charts 
from patients hospitalized following a suicide attempt, 103 patients met all of the inclusion 
criteria, which were: no diagnosis of bipolar spectrum disorder; diagnosis of major depressive 
disorder; and a recorded suicide attempt within four weeks prior to hospitalization. The study 
population consisted of 69 women and 34 men with a mean age of 49.21 years (SD 14.56 years). 
The study found no significant correlation between antidepressants and suicide attempts. 
However, the researchers also suggested that SSRIs may be less effective in treating suicidal 
depressed patients who are hospitalized in comparison to antidepressants that have effects on 
multiple neurotransmitters.
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Cougnard et al. (2008) examined whether antidepressants decrease suicide. The 
participants were broken into three age groups (children and adolescents 10 to 19 years of age, 
adults 20 to 64 years old, and elderly patients 65 years of age or older) diagnosed with major 
depression. Data was extracted from both published studies and databases of the French general 
population. The number of suicides induced or avoided by antidepressant therapy and no 
antidepressant therapy was then estimated. The researchers estimated that antidepressant therapy 
would prevent 31.9% of suicides in depressed subjects over one year in comparison to no 
antidepressant therapy in the 10 to 19 year age group, 32.2% of suicides in adult depressed 
subjects, and 32.3% of suicides in elderly depressed patients. The finding that antidepressants 
act as a protective factor against suicide can also be carried into the general population. While 
this study did include a large population of subjects, the simplified model constructed for the 
purpose of this study is a weakness.
When it comes to the link between antidepressant use and suicidality, there are many 
unknown factors. Many studies rely solely on the report of the patient when determining 
whether or not they are taking antidepressants. However, some toxicology studies have found 
that only a small number of suicide victims have traces of antidepressants in their system. 
Isacsson, Holmgren, and Ahlner (2005) tested this theory. They believed that if SSRIs posed an 
increased risk of suicide, the medication should be found more often in toxicology reports. This 
study analyzed the toxicology reports of 14,857 suicide cases in Sweden between the years 1992 
also looked at 4,301 deaths by uncertain causes to ensure that deaths by 
overdose were not overlooked. Seventy-one percent of the cases studies were men and the 
median age was 49 years. The study group was then compared to a control group consisting of 
26,422 cases determined to be death by accident or natural causes. The control group consisted
and 2000. The study
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of 73% men and a median age of 55 years. The study also analyzed 52 suicides in children under 
15 years-of-age and 326 cases of suicide in adolescents between the age of 15 and 19.
The study by Isacsson, Holmgren, and Ahlner (2005) found that only 7 of the 52 cases of 
suicide in children under age 15 were positive for any kind of anti-depressant, and no cases were 
positive for SSRIs, compared to 5 cases of the 998 total persons in the control group under 15 
years of age. In the age group of 15 to 19, 13 of 326 suicide cases were positive for 
antidepressants. Only six of these cases were positive for SSRIs. This is compared to anti­
depressant detection in five cases (three of which were SSRIs) of the 577 total cases in the 15-19 
control group. Antidepressants were detected in only 13% of children, 4% of adolescents, and 
23% of suicide cases among all age groups. As a result of this study, the researchers reported that 
SSRIs were detected at lower rates than other anti-depressants in suicide victims, and suggested 
that under-treatment with antidepressants is still an issue.
Isacsson, Holmgren, and Ahlner (2009) repeated a similar study in Sweden to include 
suicides (N=16,937), natural deaths (N=12,181) occurring between 1995 and 2005. The mean 
age of the suicide group and control group combined was 50.6 years, with 70.8% being male. 
During the period from 1995 to 2005, the number of suicides exposed to antidepressants 
increased by 46% while the suicides decreased by 18.6%. Among the control group, the use of 
anti-depressants increased by 109%. The authors suggested that antidepressants reduced the risk 
of suicide by 43%.
A smaller study of 253 persons conducted by Cortes et al., (2011) found similar results. 
This retrospective study was conducted on suicide victims aged 24 years-of-age or younger in 
Miami-Dade County Florida from 1990 to 2007. The researchers then reviewed demographic 
data, psychosocial factors, suicide characteristics, and toxicology reports. The study found that
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approximately 90% (N=228) had no trace of antidepressants on review of the serum toxicology 
report. Six percent bf these antidepressants were found to be SSRIs. Interestingly, the 
researchers also noted several other substances in these patients upon review of the toxicology 
report, including: 31.6% (N=80) showed a presence of alcohol, while 17.8% (N=45), opioids 
6.7% (N=17), hallucinogens 1.2% (N=3), benzodiazepines 12.3% (N=31); other types 13% 
(N=33); and unknown 5.9% (N=15). Ninety seven patients (38.3%) had no substances shown on 
the toxicology report. The suicide victims studied were 85% male and 53.4% were Hispanic. 
Women were more frequently found to have positive results for antidepressants on the 
toxicology reports than men.
Leon, et al., (2004) conducted a small toxicological study on 66 suicide victims less than 
18 years-of-age between 1993 and 1998 evaluated whether or not serum blood samples revealed 
the presence of anti-depressants. Because the longest acting anti-depressant, fluoxetine, has a 
half-life of 21 hours, 12 victims (who lived for 3 days or more following their suicidal act) were 
excluded from the study, leaving 54 persons available for toxicological testing. The age range of 
the deceased ranged from 10 to 17 years-of-age with seven being younger than 13 years of age. 
The ethnicities of the deceased were evenly split between Hispanics, African Americans, and 
Caucasians. Additionally, 75 percent of the deceased were males. The toxicological results 
found that paroxetine was not present in any of the suicide victims, two screened positive for the 
presence of imipramine, and two screened positive for fluoxetine. While the study is small, it 
does confirm, as do the other toxicological reports discussed above, that the large majority of 
suicide victims are not taking anti-depressants at the time of their death.
In addition to serum toxicology levels, genetic predisposition is another factor that is not 
commonly analyzed in studies questioning the link between antidepressants and suicidality. A
study by Perroud, et al., (2009) examined whether emergent suicidal ideation during 
antidepressant treatment could be driven by genetic factors. The researchers selected nine genes 
involved in neurotrophic, serotonergic, and noradrenergic pathways. The participants (N=796) 
were then treated with antidepressants and were studied for emergence of suicidal ideation and 
genetic variances over a 12 week time frame. Participants were included in this study if they met 
criteria for an episode of major depression that was of at least moderate severity. Patients were 
randomly assigned to either escitalopram or nortriptyline treatment groups. However, patients 
that had a contraindication to taking one of the medications were assigned to the other anti­
depressant group. Participants were 18 to 72 years of age. Participants with a primary substance 
misuse or primary organic disease, pregnancy or lactation, current treatment with an 
antipsychotic or mood stabilizer, history of hypomanic or manic episode, mood incongruent 
psychotic symptoms, or a first degree relative with a bipolar disorder diagnosis or schizophrenia, 
were excluded from the study.
In their study, Perroud et al. (2009) found that a larger number of males experienced 
suicidal ideation when taking nortriptyline if they had the A allele compared to the C allele. The 
study also found that “variants in the genes encoding BDNF and its receptor (NTRK2) were 
associated with an increase in suicidal ideation during antidepressant treatment in subjects 
suffering from major depressive disorder” (Perroud et al., p. 2524). The researchers, “found an 
even stronger effect for an interaction between the known functional BDNP-LCPR GT (n) 
polymorphism and SNPs in the 3’ region of NTRK2” (Perroud et al., p. 2524). The small 
sample size of participants is a weakness of this study. In addition, the limited number of 
participants under 25 and over 65 years-of-age made it impossible to make any assumptions on 
how genetic polymorphisms may affect these age groups.
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Ecological studies have analyzed the number of anti-depressant prescriptions provided to 
a population against changes in suicide rates. Studies conducted since 2005 have consistently 
shown an inverse correlation between the number of anti-depressants prescribed and the number 
of completed suicides (Castelpietra, et al., 2008; Henriksson, et al., 2006; Korkeila, et al., 2007). 
One study conducted in Finland, a country where two-thirds of the population suffer from a 
depressive disorder, analyzed the number of anti-depressants prescribed and the number of 
suicides between 1994 and 2001. There were a total number of 1,387 completed suicides in 
1994 compared to 1,204 completed suicides in 2001. During that same time period, the number 
individuals prescribed anti-depressants increased from 140,438 in 1994 to 272,370 in 2001. The 
study found that an increase in the number of anti-depressants prescribed was significantly 
associated with a decrease in suicide rates (16 percent in men and 14 percent in women) after 
gender, age, and region were taken into account (Korkeila et al., 2007).
A similar study done among individuals living in the Fruili Venezia Giulia region of Italy 
(which is the region of Italy found to have the highest rate of suicide in the country) between the 
years of 1997 and 2006 found that the use of anti-depressants increased from 11.9 individuals 
users per 1,000 inhabitants in 1997 to 56.7 individual users per inhabitants in 2006. During that 
time frame, suicides rates decreased from 13.8 per 100,000 in 1997 to 9.1 per 100,000 in 2001. 
This equates to a relative suicide risk reduction of 35 percent in women and 34 percent in men 
(Castelpietra, et al., 2008). Another ecological study in done in Jamtland county, Sweden from 
1995-2002 focused on educating general practitioners as a way to improve treatment in patients 
struggling with depression in Jamtland county, Sweden, but also analyzed whether the program 
had an impact on the number of anti-depressants prescribed and suicide rates. The study found 
that sales of anti-depressants increased 161% in Jamtland County between 1995 and 2002. With
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regard to anti-depressant use and suicide rates, the study found that the increased use of anti­
depressants were associated with a decreased rate of suicide of 30 percent and 47 percent in men 
and women of Jamtland County, respectively (Henriksson, & Isacsson, 2006).
All three of the ecological studies discussed above found that the antidepressants 
prescribed were primarily from the SSRI class (Castelpietra, et al., 2008; Korkelia et al., 2007; 
Henriksson & Isacsson, 2006). Two of the three studies noted that more women than men were 
prescribed anti-depressants (Henriksson, & Isacsson, 2006) and all three studies found that more 
men committed suicide than women (Castelpietra, et al., 2008; Korkelia et al., 2007; Henriksson 
& Isacsson, 2006). One main weakness of all three studies is that none examined serum blood 
levels of those who had committed suicide for the presence of anti-depressants.
A cohort study performed in Finland included 100 percent of people hospitalized for 
suicide attempts between 1997 and 2003. The study population was 15,390 patients, including 
7,466 males and 7,924 females. The researchers calculated the relative risk of suicide attempts, 
suicide completions, and overall mortality of patients being treated with anti-depressants versus 
no treatment with anti-depressants. The anti-depressants included were TCA (amitriptyline or 
doxepin), SSRI (fluoxetine, citalopram, paroxetine, sertraline, or fluvoxamine), and SNA 
(mianserin, mirtazapine, or venlafaxine). The results of the study found that, while there was an 
increased risk of suicide attempts in patients taking anti-depressants versus no treatment with 
antidepressants, there was no increased risk of suicide completions. Additionally, the study 
found a decreased mortality rate, particularly in the rate of cardiovascular-related deaths 
(Tiihonen, et al., 2006).
Furthermore, the American College of Neuropsychopharmacology (ACNP) formed a task
force that reviewed several studies, including the meta-analysis which was conducted by the
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FDA and later resulted in the black box warning for anti-depressants, epidemiologic studies, 
RCTs and post-mortem toxicological studies. The ACNP found that, while the FDAs meta­
analysis does show a small increase in suicide attempts or suicidal thinking in youths, the effect 
varies across the RCTs reviewed in the meta-analysis. The ACNP further determined that, while 
the variance could be due to a difference between medications, it is also possible that the 
variance could be due to an error in measurement. The epidemiologic and post-mortem studies 
as well as cohort surveys reviewed by the ACNP did not support an increase in suicidal acts or 
suicide, and instead found a possible beneficial effect between anti-depressants and suicidality. 
The ACNP also surmised that, based on the post-mortem toxicological youth studies, only a 
small number of youth who commit suicide are taking anti-depressants at the time of suicide 
(Mann, et al., 2006).
Methods
A systematic literature search was conducted to identify randomized controlled trials and 
epidemiologic studies indexed between 2005 and 2012. Cochrane Library, CINAHL (Headings), 
PubMed (MeSH), and Psychlnfo (Thesaurus) were utilized to conduct the search. The search 
terms utilized for the purpose of this project were “antidepressive agents” and “‘suicide” or 
“suicidal ideation.” Two separate searches were performed in CINAHL (Headings), PubMed 
(MeSH), and Psychlnfo (Thesaurus). The initial search included the search terms previously 
listed, but limited the search to only randomized control trials. The second search included the 
initial search terms, but limited the search to epidemiologic studies.
Cochrane Library was first searched for studies using these terms. This search returned 
26 results, 21 of which were published after 2004. Of those results, three were found to be of 
particular interest for the purposes of this project.
CINAHL (Headings) was searched next using the same terms. The search limited to 
randomized controlled trials returned 323 results. Limiting the results to PDF full text only 
returned 50 results. Excluding studies published prior to 2005 further confined results to 40 
studies. Including only peer reviewed articles limited the results to 34. Further review of these 
results determined that four of the studies were pertinent to the topic of this paper. A second 
search was then performed in CINAHL (Headings) to include prospective studies. This search 
returned 607 results. Further limiting this search to PDF full text only returned 99 results. 
Including only studies published between 2005 and 2012 further confined the number of results 
to 72 articles. Including only those studies that had been peer reviewed and available in the 
English language limited the results to 65. Review of the resulting prospective studies revealed 
that six were appropriate for further review for this paper.
The PubMed database was then searched using the same terms (“antidepressive agents” 
and '‘suicide” or “suicidal ideation”). The search was further limited to include randomized 
controlled trials (as a publication type). This search returned 78 results. Delimiting the search 
further to publications dates between 2005 and 2012 returned a total of 65 articles. Limiting the 
articles to full text only further limited the number of articles to 63. Further review of these 
articles determined that six were pertinent to this project. One of the articles found pertinent to 
the project was a task force review of multiple study types (meta-analysis, RCTs, epidemiologic, 
and post-mortem toxicology studies) that examined the correlation between anti-depressants and 
suicidality among children and adolescents (Mann, et al., 2006). A second search in PubMed 
using the terms returned 35 results when the criteria was further delimited to full text 
prospective studies published between 2005 and 2012. Of these studies, two were appropriate 
for the purpose of this paper. A third search (using the same terms) was also conducted in
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PubMed (MeSH) to include the term “epidemiologic studies.” The initial search returned 480 
results. Further limiting the results to full-text articles published between 2005 and 2012 
returned 351 results. Of the studies reviewed, 12 were found pertinent to the topic of this paper.
A search of the Psychlnfo (Thesaurus) database was then searched using the terms 
“antidepressant drugs” and “suicide” or “suicidal ideation” and “clinical trials” returned 32 
results. Further limiting the search to articles published between 2005 and 2012 returned 30 
results. When the author further delimited results by adding criteria for peer reviewed and full 
text articles only, seven articles were returned. Further review of these articles revealed that two 
were appropriate for use in this project. There were no full text results for prospective studies 
related to the key terms searched in Psychlnfo (Thesaurus).
The author also reviewed the reference lists of the articles chosen for inclusion in the 
paper, and utilized three studies from those lists. One of the studies chosen was published in 
2004; however, it provided important post-mortem toxicological evidence of youth suicide and 
anti-depressant use and thus, was included in the study. All of these articles focused on the 
presence of serum antidepressant level during post-mortem autopsy. Kim Gregg, RN, CNS, was 
consulted to review and provide recommendations and guidance of this project. The hopes is 
that this project will affect a change in clinical practice by revealing whether studies that 
question the link between anti-depressants and suicidality have taken confounding factors into 
consideration when reporting their results. If that is not the case, then whether or not 




A copy of both the written paper and the Power Point presentation for this project was 
provided to Registered Nurses and Psychiatrists who are members of the Integrated Behavioral 
Health Team at Mayo, Clinical Nurse Specialists who are members of the Psychiatry Department 
at Mayo, and student colleagues in the Mental Health Nurse Practitioner Program at the 
University of North Dakota for feedback. Colleagues provided positive feedback regarding the 
types of studies that were reviewed for the project. The colleagues noted the tremendous impact 
keeping meticulous medical records (such as those depicted in the studies performed in Finland 
and Sweden) could have on both medical research and patient outcomes. Most were particularly 
interested in toxicological and genetic findings from the studies reviewed.
Discussion and Implications for Nursing
According to the National Institute of Mental Health (NIMH), the U.S. suicide rate was 
11.3 deaths per 100,000 in the general population in 2007 (NIMH, n.d.). Since more than 95% 
of people who die of suicide suffer from depression or other mental disorder (Schreiber, 
Culpepper, & Fife, 2012), it can be deduced that the suicide rate is much higher in the sub­
population of those who are struggling with mental illness in comparison to the general 
population. Controlled studies completed with a goal of showing whether there is a correlation 
between anti-depressants and suicide or suicidal thoughts and/or behaviors on the sub-population 
mentioned above often exclude patients who are at higher risk for developing suicide or suicidal 
ideation/behaviors due to ethical issues (Tiihonen et al., 2007). It would make sense that the 
exclusion of participants at higher risk for suicide from controlled studies would, in turn, cause 
controlled studies to have lower rates of suicide or suicidal ideation/behavior in comparison to 
epidemiologic studies (Howland, 2006). However, several epidemiologic studies have shown
that treatment with anti-depressants decrease the rate of suicide (Tiihonen, et al., 2006; Olfson, 
Marcus, & Shaffer, 2006; Castelpietra, et al., 2008).
It is crucial to delineate any confounding factors (other than the use of anti-depressants) 
that may contribute to an increase in suicide and or suicidal thoughts/behaviors in these studies 
in order to authentically state that anti-depressant therapy is the sole cause of a participant’s 
suicidal thoughts and/or behaviors. Making claims that anti-depressants increase suicide and/or 
suicidal thoughts/behaviors without fully exploring every other plausible explanation is not only 
unfounded, but creates a falsity throughout the medical field and in the public eye that can 
substantially impact patient treatment and outcomes.
There is concern among both health care providers and the lay public with regard to the 
correlation between anti-depressant therapy and suicidality. While the FDA warning label was 
based on a meta-analysis that reviewed the correlation between anti-depressant use and 
suicidality, no completed suicides were reported during this study (Valuck, Orton, & Libby, 
2009). There are too many unknowns to determine whether or a direct correlation between 
antidepressant treatment and suicidality exists. Genetic factors, comorbid medical or 
psychological disorders, and history of prior self-harm/suicide attempts are just a few of the 
unknown factors that could be influencing the study outcomes. These factors could play a role 
in suicidal thoughts or behaviors in both adolescents and adults, and while these thoughts and 
behaviors may occur in conjunction with anti-depressant treatment, it should not be an indication 
that the anti-depressants caused the thoughts or behaviors to occur.
One study of suicide attempts and non-suicidal self-injury in adolescents (ages 12 to 18 
years-of-age) with treatment resistant depression found that 47.4% reported non-suicidal self- 
injury at baseline. National surveillance data also indicates that approximately 6.3% of high
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school students attempt suicide (Rosenbaum-Asarnow et al., 2011). It is difficult to show that 
anti-depressants cause increased suicidality in adolescents, where self-harm behavior is common.
Further research is needed to determine whether there is a link correlating antidepressants 
and suicide levels. The lack of studies that include drawing toxicological serum levels alone can 
impact the study findings because patient report alone is used to determine whether or not 
participants are taking their anti-depressants. It is of particular importance to obtain serum anti­
depressant levels in children, adolescents, and adults who participate in self-harm, attempt 
suicide, or complete suicide, especially since post-mortem studies have consistently found that 
over 80 percent of depressed adult suicide victims are not taking anti-depressants at the time of 
their death (Mann, et al., 2006). Another area for possible research is genetic studies. Testing 
for factors, such as BDNF, may also prove helpful in decreasing suicidality in patients in the 
future.
As nurses, there are many things that we can do to promote mental wellness among our 
patients while promoting health policy in our communities. Continued education both among the 
public and among the health care community is essential in order to recognize and accurately 
treat patients with mental illness. Advocating for our patients by helping to increase the 
diagnosis and treatment of mental illness in the outpatient setting is one step that could have a 
very positive impact on patient outcome. Another positive step would be creating awareness 
programs in our middle schools and high schools, where the risk for self-harm behavior and 
suicide attempts is high. In order to effectively improve patient outcomes where mental illness is 
concerned, it is essential to evaluate each community on an individual basis. High risk areas in 
which there is potential for improved outcomes should be identifies, and programs tailored to 




The correlation between mental illness and suicidality is a huge health concern. While 
many studies have been done to identify whether anti-depressant treatment is directly correlated 
with an increase in suicidality, these studies do not take into account many of the confounding 
factors that could increase suicidality independent from anti-depressant use. Ecological studies 
have consistently found a decrease in suicide rates with a corresponding increase in anti­
depressant use. Toxicological studies have also consistently found that the majority of patients 
who commit suicide do not have anti-depressants present in their system at the time of death. 
However, few studies include toxicological serum levels to ensure compliance with anti­
depressants. Some studies have also correlated a decreased level of BDNF with increased 
suicidality, yet few studies have considered low BDNF levels as a possible variable for increased 
suicidality.
The studies reviewed for evidence of whether or not anti-depressants increase suicidality 
in patients do not account for many of the factors that increase the risk for suicidality 
independent from anti-depressant use. Because of this, it is not possible to say whether or not 
there is a correlation between the use of anti-depressants and suicidality. Furthermore, it is 
important to separate the terms of self-injurious behavior, suicide attempt, and suicide 
completion instead of using the term suicidality to discuss the effects anti-depressants have on 
behaviors. There is evidence that the risk of suicidality increases in the initial four weeks 
following treatment for depression (whether it is psychotherapy or medication based), but then 
decreases significantly after that time. It is imperative to monitor patients closely for suicidality 
after initiating treatment for mental illness. However, the fear that antidepressants may cause 
suicidality in some patients should not overshadow the need to treat them. There is strong
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evidence to support that anti-depressant treatment offers long term benefit to patients struggling 
with mental illness in relation to suicide risk.
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Research Based Findings of Anti-depressant Therapy and Suicidality: Power Point Presentation
Research Based Findings of Anti- 
Depressant Therapy and Suicidality
Purpose of the Project
» Review literature related to anti-depressant 
therapy and suicidality including:
• Suicidal ideation 
Suicide attempts 
Suicide completions
► Determine whether or not confounding 
factors that might contribute to suicidality 
were considered in the study results
► Review studies that may provide areas 
needing additional research (i.e. toxicological 
levels and genetic factors)
Melissa Webster 
University of North Dakota
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Theoretical Framework
* Biopsychosocial model was utilized to guide 
this project
> The biopsychosocial model allows fo ra  
multi-faceted analysis regarding the 
reasoning for the development of suicidality 
in patients
Methods
► Systematic literature searches were conducted In Cochrane 
Library, CINAHL (Headings), PubMed (MeSH), and Psychlnfo 
(Thesarus)
* Search terms utilized were ' antidepressive agents" and 
"suicide" or “suicidal ideation"
» Search criteria were delimited to full text articles in the 
English language with publication dates between 2005 and 
2012
► Randomized controlled trials and epidemiological studies (!,«, 
cohort, retrospective, or observational) fitting the criteria 
above were identified and were further reviewed for 
pertinence
»" Review of the reference list of the articles selected for use in 
the project were reviewed, and three articles from these 
reference lists were utilized in the project
»■ Kim Gregg, RN, CHS, was consulted for guidance throughout
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Mental Illness and Suicide
*
*
Mental illnesses associated with the highest risk of suicide 
include:
* Depression
Anxiety disorders (including panic disorder and PTSD)
Alcoholism 
Substance abuse
* Bipolar disorder 
Schizophrenia 
Personality Disorder
* Delirium (Schr#tb«<\ Culpepper, and Fife, 2012)
Additional factors that increase suicide risk are:
* Prior psychiatric hospitalization
» Prior history of self-harm behavior (uder. 200n
Prior history of suicide attempts (this is the strongest single predictor 
of future suicide attempts )
(Otreer, lancw. & Strous. 20091
Depression
► One of the most common mental health disorders 
associated with increased suicide risk
► Defined as an affective disorder characterized by at 
least five of the following symptoms for at least 
two weeks:




Psychomotor agitation retardation 
Difficulty concentrating
Diminished interest in activities which used to be 
pleasurable




* Depression can also profoundly effects an 
individual's interpersonal relationships as well as 
work and school function
► #1 cause of missed work and disability in U.S
(Cantro, 2011)
► Estimated 20% of women and 12 % of men in U.S, 
will experience depression during their lifetime
(Porth &Matfin, 2009)
► Of those who experience one episode of 
depression, the rate of recurrence is approximately
50% (CDC, 201 1)
Suicide Statistics
p Suicide is the third leading cause of death in those 
under age 45 in the U.S.
• It is the 10th leading cause of death in the world
(Doigm. 2012)
* U.S. suicide rate in the general population is 
11.3/100,000 people
(NIMH, nd)
► Every year in the U.S. 30,000 people die of suicide
An additional 650,000 are treated in emergency rooms 
annually following suicide attempts
► Of those who complete suicide, more than 95% 
have at least one psychiatric diagnosis




> Men are 4xs more likely than women to die of suicide
> Rate of suicide in general public is 11.3 per 100,000 people 
* Rate is increased to 14,3 per 100,000 people in men 65 years and
older
Rate is 47 per 100,000 people in non-Hispanic white men aged 85
years and older
(NIMH, 2012)
t Adolescents ages 12 to 18 years of age have suicide attempt 
rate of 6.496
Rate of non-suicidal self-injury among adolescents 12-16 is 4 7 ,7 $
(Rosenbaum-Asarnow, et al., 2011)
> One study found that patients with mental illness had a 
suicide rate of 27 times greater than that of the general 
population
(Simon, 2012)
im p o rtan ce  o f d eterm in in g  co rre lation  
b etw een  a n t i-d e p re ssa n t u se  and su ic id a lity
► Anti-depressants are one of the most common 
treatments for depression, anxiety, and other mental 
illnesses.
» 2004: The (FDA) mandated a black box warning be 
added to anti-depressant medications in order to alert 
patients of increased risk of suicidal thoughts in the 
pediatric and adolescent population (Friedman & Leon, 2<x>7)
► 2007: FDA mandated that the black box warning be 
expanded further to include patients between 18 to 24 
years-of-age
*■ The mandated warning was based on a meta-analysis 
that included no completed suicides and infrequent 
suicide attempts
Clinical significance was only found when endpoints 
of when suicidal ideation and possible suicidal
(Valuck, Orton, & Libby, 2009)
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impact of FDA Warning
► A common reason that patients do not report 
symptoms of depression is the fear an anti­
depressant will be recommended
► Decreased both the rates of diagnosing depression 
and treating patients with anti-depressants
(Simon, 2012)
► These negative impacts are unfortunate because
studies have found that anti-depressant treatment 
is associated with significantly lower rates of 
suicidal mortality (Simon, 2012)
Literature Review
> Rucci et al.t 2011
Randomly assigned 318 participants to receive SSRI
(escitalopram) treatment or psychotherapy (IPT) groups
Participants selected from two University Outpatient Clinics
between April 2003 and April 2008
210 female participants, 109 male participants
90 participants were experiencing their first episode of
depression
201 participants had at least 2 depressive episodes 
59 participants had suicidal ideation and 1 had a plan at 
time of pretreatment interview
The goal of the study was to determine whether or not the 
participants in the groups would experience emergent 
suicidal ideation (ESI) during treatment
Literature Review
► Rucci et al.f 2011, (Cont.)
Strengths:
* Participants were referred from clinic setting, not from the general 
population:
* Two commonly used interventions (S5RI and IPT treatments) were 
compared
* Participants experiencing suicidal ideation were included in the study 
> limitations:
* Participant pool was 7 2 * female
* Study did not include those under 19 or over 64 years-of-age
* Results are limited to the use of escitalopram versus other medications
* Patients with a plan to commit suicide, those with psychotic depression, 
current alcohol or drug use, or newly diagnosed and unstable physical 
ill ness were excluded
Literature Review
> Rucci, et al., 2011
Findings
* None of participants (N=21) who had history of 
previous suicide attempts developed ESI during the 
study period
* Of 231 participants who denied suicidal thoughts at 
baseline, 32 developed ESI at some point during 
follow-up. Timeline for ESI development is as 
follows:
• Less than 4 weeks: N *  13
• 5 to 8 w eeks: N=*9
• After 8 weeks: N *  10
* Time to ESI was significantly longer for the SSRI 
group than in the IPT group
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Literature Review
» Mulder, Joyce, & Frampton (2008)
Coal; To determine whether patients who were either currently 
experiencing s.i. or had a history of suicide attempts with anti­
depressants reduced those thoughts behaviors over time 
; 195 participants
Referred from psychiatric emergency services, community mental 
health centers, and general practitioners between 1995 and 2001 
» Inclusion criteria:
-I  S y*tr*-of-ag« or old* r 
•primary current diagnosis of major dtprtssion 
antid«pr®ssants
-willing and abl* to giv* Informed content
-Met criteria for bipolar II disorder, melancholia, atypical depression, recurrent 
depression, or chronic depression
< Exclusion criteria:
-Irtastfetding/pregnant i ltaty to become pregnant 
-Major medical disorder that could complicate treatment 
-Sever* drug alcohotdependence 
-History of mania schizoaffective disorder.'sOiizophrenia
Literature Review
» Mulderjoyce, & Frampton (2008), cont.
► Statistics:
57,496 female
Mean age 32.2 years (Standard Deviation 11.4)
34.696 reported at least moderate suicidal ideation 
39 patients reported a suicide attempt within the 6 months 
prior to treatment
12 participants reported more than one suicide attempt 
within the 6 months prior to treatment
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Literature Review
* Mulder, Joyce,& Frampton (2008), cont.
* Randomly assigned to groups for treatment with either 
nortriptyline or fluoxetine
Participants were followed for 6 months
They were asked if they experienced suicidal ideation in the
past 14 days.
They were evaluated for suicide attempts since the beginning 
of the study six times in the 6 month period 
Participants who did not respond to the initial medication at 6 
weeks after treatment were switched to the other medication 
group
If the patients didn’t respond to the second medication, they 
were treated with a combination of the two mediations
if there was no response with combination treatment, the 
clinician used whatever medication they felt was indicated
Literature Review
► Mulder Joyce, &  Framptom, (2008) Results:
Patients were divided into three groups based on their treatment
outcome
Patients who recovered and remained well until the six-month
assessment
Patients who either achieved remission or recovered but subsequently
relapsed
* Patients with persistent depression
176 of the 195 participants remained at the 6 month follow-up
* 9 participants left the area, 1 participant withdrew without treatment 
and later committed suicide
* 66K of patients remained on either fluoxetine or nortriptyline at 6 
month follow-up
* 24 patients had stopped the medication because they either elected 
to or found it intolerable
* 29 patients attempted suicide (compared to the 51 participants who 
attempted suicide in the 6 months prior to the study)
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i Mulder,Joyce, &  Framptom, 2008- Results (cont). 
Suicidal ideation was reduced by 33% in the first 3 
weeks of treatment* 38% over course of 6 months 
The number of suicides dropped to 50%comparedto 
6 month period prior to treatment 
None of the 5 participants who had no suicidal 
ideation or suicide attempts in the six months prior to 




> Seemuller, et al. (2009)
Naturalistic study that included 1,014 participants 
Participants were recruited from 7 German psychiatric 
university hospitals 
® Inclusion criteria:
* 18-65 years of age
* Willing and able to sign informed consent
* Diagnosis meeting criteria for any major depressive episode 
13 7 of the participants had attempted suicide 
immediately prior to hospitalization
10 participants attempted suicide and two 
participants completed suicide during treatment
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► Results: Seemuller.etal. (2009)
14.4% of participants experienced worsening of 
suicidal ideation
Patients under 45 years-of-age were more likely to 
experience ESI
Suicide rates among study participants were much 
higher than the general population 
Suicide rates were only slightly elevated compared 
with that of other RCTs
Literature Review
Literature Review
» Olmer, lancu, and Strous (2012)
Retrospective study
Reviewed adult patients admitted to the Beer Yaakov Mental 
Health Center from 2000-2007 with diagnosis of MDD 
Coal of study was to analyze whether anti-depressants 
have a significant relationship in suicide attempts
* Inclusion criteria:
* Diagnosis of MDD
* Recorded suicide attempt within four weeks prior to 
hospitalization
* Exclusion criteria:
* Diagnosis of bipolar spectrum disorder
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> Olrrter, lancu, and Strous (2012), cont
> Study population
* 103 patients, including 69 women and 34 women
* Mean age of 49.21 (standard deviation oOf 14.56 years)
> Results
No significant correlation between anti-depressants and 
suicide attempts
Researchers also suggested that SSRls may be less effective 
in treating hospitalized suicidal depressed patients than 




>* Cougnard, et al. (2008)
► Aim of the study was to analyze whether anti­
depressants decrease suicide
* Data for the study was extracted from both 
published studies and databases of the French 
General population
* Participants broken into 3 age groups:
* Children and adolescents ages 10-19 years of age
* Adults 20-64 years of age
* Patients 65 years of age or older
► Number of suicides either induced or avoided by 
anti-depressants was estimated
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* Cougnard, et a!. (2008), cont,
» Results:
In the 10-19 year age group
* Ami-depressant therapy would prevent an estimated 
31.9% of suicides in depressed subjects over one year in 
compared to no anti-depressant therapy
In the 20-64 year age group
* Anti-depressant therapy would prevent an estimated 
32.2% of suicides in depressed subjects over one year in 
compared to no anti-depressant therapy
• In the age group over 65 years-of-age
* Anti-depressant therapy would prevent an estimated 
32.3% of suicides in depressed subjects over one year In 
compared to no anti-depressant therapy
Literature Review
Literature Review
» Isacsson, Holmgren, and Ahlner(2005)
i Tested the theory that traces of anti-depressants 
would be found commonly in suicide victims if 
anti-depressants did increase suicide risk
► Toxicology reports of 14,857 suicide cases in 
Sweden from 1992-2000 were analyzed
► Study also examined a control group of 26,422 
who died of natural or accidental causes
i Median age in suicide group was 49 years old vs. 
55 years old in control group
» 52 suicides in children under 15 and 326 suicides 
in adolescents aged 15-19 were also analyzed
49
*■ Isacsson, Holmgren, and Ahler (2005), cont.
> Findings
» Under 15 years of age:
* 7 of 52 cases were positive for ami-depressants, although 
none were positive for SSRis, vs. 4 cases among the 998 
controls in this age group
* Age 15-19
* 13 of 326 suicide cases were positive for anti-depressants, 
only 6 of the 13 cases were positive for SSRIs
* 5 cases among the 577 controls were positive for anti­
depressants (3 were positive for SSRis)
* Overall outcome
* Anti-depressants detected in 13% of children, 4% of 




> Isacsson, Holmgren, and Ahlner (2009)
* Study similar to 2005 was performed
* Evaluated the number of anti-depressants prescribed in 
1995 and 2005 to the number of suicides that occurred 
in 1995 and 2005
* 16,937 suicides in Sweden between 1995-2005 were 
examined and compared it to a control group of 12,181 
natural deaths
* Findings:
Anti-depressant use increased by 46% in the suicide group 
while suicides decreased by 18.6%
In the control group, the use of anti-depressants increased by 
109%
Anti-deoressants reduced suicide risk by 43%
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Literature Review
* Cortes etal. (2011)
» Retrospective study of suicide victims 24 years-of-age 
or younger in Miami Dade County, Florida from 1990-
► 253 cases were analyzed
* Demographic data, suicide characteristics, psychosocial 
factors, and toxicology reports were reviewed
► Demographics
* 85% men (N=215)
Average age 20.3 years (standard deviation of 2.6 with a range 
of 11 -24 years)
* 53.4% (N=l 35)Hispanic; 26.9% (N=68) Caucasian; f 5,4% 
(N=39) African American; 4.3%<N=ll)of other ethnic origin




91% (N=231) had undetermined family history of mental 
illness
4% (N-9) had documented family history of at least one 
family member with mental Illness 
Almost 45% (N=l 12) of cases had a personal history of 
mental illness
8% (N—21) of cases known to have a history of treatment 
for mental illness
* 19% (N=49) had a known legal history
• 76% (N=l 92} were known to have had stressors of some
51
i Cortes, et al., 2011 
i Toxicology Report
90% (N=228) did not have any kind of anti-depressants 
present
6% (N=15) were positive for SSRI, SNRI, TCCA, or other type
of anti-depressant
31.6% (N=80) positive for alcohol
17.8% (N=45) positive for stimulants
6.7% (N=17) positive for opioids
1.2%fN=3) positive for hallucinogens
12.3% fN=31) positive for benzodiazepines
Literature Review
Literature Review
> Cortes et al., cont
► Findings
Women and those at least 19 years of age were found to 
have been using antidepressants compared to men 
1 3% women were positive for presence of antidepressants 
compared to 4% of men
90% of the sample did not have any kind of antidepressant 
in their system
No difference in detection of anti-depressants was found 
between Hispanic and Non-Hispanic cases 
* Alcohol was present in 31.6% of the cases
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Literature Review
► Leon, et al. (2004)
Small toxicological study of 66 suicide victims less than 18 
years-of-age between 1993-1998 
Study evaluated whether or not anti-depressants were 
present in serum blood samples of suicide victims
* Victims who lived for 3 days or longer after the suicidal act 
were excluded as anti-depressant levels would be 
undetectable after that time
* 12 were excluded as a result, leaving 54 available for serum testing
* Age range was 10 to 1 7 years of age (7 were younger than 
13)
Ethnicity was evenly divided between Hispanic, African 
American, and Caucasian
* 7596 were males
Literature Review
> Leon, et al. (2004)
> Findings:
Paroxetine was not present in any of the cases 
Imipramine was present in two cases 
Fluoxetine was present in two cases 
The large majority of victims were not taking anti­
depressants at the time of their death
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i Perroud,2009
► Examined whether emergent suicidal ideation (ESI) 
during antidepressant treatment could be driven by 
genetic factors
► 9 genes that involved neurotrophic, serotonergic, 
and noradrenergic pathways were selected
► 796 participants were treated with antidepressants 
and studied for genetic variances and ESI during a 
12 week time frame
Literature Review
Literature Review
* Perroud, et al., (2009), cont.
* Inclusion criteria:
* 18-72 years of age
Must have met criteria for an episode of major depression that 
was of at least moderate severity
» Exclusion criteria:
First degree relative with a diagnosis of bipolar disorder or 
schizophrenia
* Primary substance misuse 
Primary organic disease 
Pregnancy or lactation
Current treatment with an antipsychotic or mood stabilizer 
History of hypo manic or manic episode
* Mood incongruent psychotic symptoms
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Literature Review
* Perroud, et ai. (2009} com.
► Method
Participants were randomly assigned to either escitalopram or nortriptyline treatment groups
Patients that had a contraindication to one of the medications were assigned to the other medication group
♦ Findings
A larger number of males experienced suicidal ideation when 
taking nortriptyline if they had the A allele compared to the C allele
Variants in the genes encoding BDNF and its receptor (NTRK2) 
were associated with an increase in suicidal ideation during antidepressant treatment in subjects suffering from major depressive disorder
The BDNP-LCPR GT (n) polymorphism and SNP in the 3* region of MTRK2 was found to have an even stronger relation to suicidal ideation
Literature Review
*■ Korkeilaetal., 2007
Analyzed the number of anti-depressants prescribed and 
compared it to the number of completed suicides in Finland 
between 1994 and 2001
• 1994;
* individuals prescribed anti-depressants= 140,438
* Completed suicides = l .387
• 2001:
* Individuals prescribed anti-depressants =272,370
* Completed suic»des=1,204 
• Findings:
* An increase in the number of anti-depressants prescribed 
was significantly associated with a decrease in suicide 
rates (16% In men and 14% in women}
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► Castelpeitra, etal. (2008)
* Study in Italy between 1997 and 2006
► Looked at the number of anti-depressants prescribed 
compared to number of completed suicides
► Anti-depressant use increased from 11.9/1,000 individuals in 
1997 to 56.7/1,000 individuals in 2006
* Suicide rates decreased from 13.8 100.000 in 1997 to 
9.1/100,000 in 2006




* Henriksson & Isacsson, (2006)
» Study done in jamtland County Sweden between 1995- 
2002
* Focused on educating general practitioners to improve 
treatment for patients struggling with depression, but 
also analyzed if the program impacted the number of 
individuals prescribed antidepressants and how the 
number of antidepressant prescriptions impacted the 
suicide rate.
» Results:
Antidepressants increased 161% between 1995 and 2002 
The increased use of antidepressants correlated with a 
decreased rate of suicide <30% in men and 47% in women)
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► Common findings among Castelpietra, et al„ 
(2008), Korkeliaet al., (2007) and Henriksson& 
Isacsson, (2006):
The majority of the anti-depressants prescribed were SSRis 
Ail three studies noted more men than women completed 
suicide
Two of the three studies noted that more women than men 
were taking antidepressants (Castelpietra et al., 2008; 
Korkelia et al., 2007)
Main weakness of all three studies is that they did not 
perform toxicological testing for presence of anti­






Cohort study done in Finland that included 100% of 
people hospitalized for suicide attempts from 1997- 
2003
* Goal was to calculate the relative risk of suicide 
attempts/completions and overall mortality of patients 
being treated with antidepressants vs. no 
antidepressant treatment
*■ Study included 15,390 patients (7,466 men and 7.924 
females)
► Antidepressants included in the study were: TCA 
(amitriptyline or doxepin),SSRI (fluoxetine, citalopram, 
paroxetine, sertraline, or fluvoxamine), and SNA
, orvenlafaxine)
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► Tiihonenet al„ <2006)
► Results:
There is an increased risk of suicide attempts with the use 
of anti-depressants, however, there was no increased risk 
of suicide completions
Also found that antidepressants increased mortality rate 




► Matin et a!., (2006)
American College of Neuropharmacology (ACNP) 
formed a task force that reviewed several studies, 
including the meta-analysis that resulted in the 
FDA black box warning
« Epidemiologic studies, RCTs, and post-mortem 
toxicological studies were also reviewed
58
» Mann et al., (2006)
» Findings
The FDA meta-analysis did show a small increase in 
suicide attempts or suicidal thinking in youths, but 
added that the findings of the RCTs reviewed for the 
meta-analysis varied
* The ACNP noted that the variance between these RCTs could 
be due to a difference between medications, or it could be 
due to an error in measurement
Postmortem and cohort surveys
* No evidence to support an increase in suicidal acts or suicide 
and instead found a possible beneficial effect between anti­
depressants and suicidaiity
■ Postmortem toxicological youth studies found only a small 
number of youth who commit suicide are taking anti­
depressants at the time of suicide
Literature Review
Implications for Nursing
r What can nurses do to improve patient outcomes? 
Educate ourselves about mental illness and pass our 
knowledge on to both the public and other health care 
providers in order to increase the diagnosis and treatment 
of mental illness
Identify populations at high risk for mental illness in the 
community
Oevelop programs geared towards the recognition and 
treatment of mental illness in order to improve patient 
outcomes
Conclusion
► Concern regarding a correlation between anti­
depressant use and suicidality have caused a 
decrease in the diagnosis and treatment of 
depression and has also caused some patients to be 
fearful of trialing antidepressants 
» The meta-analysis utilized by the FDA to implement 
the mandatory black box warning included no 
completed suicides, infrequent suicide attempts, and 
only found clinical significance related to a 
correlation between antidepressant use and 
suicidality when the endpoints of suicidal ideation 
and possible suicidal ideation were added as 
endpoints (Valuck, Orton, & Libby, 2009)
Conclusion
» The term suicidality should be broken into terms including 
suicidal ideation, suicide attempt, and suicide completions 
because there is evidence to support that antidepressant 
therapy is associated with significantly lower rates of suicidal 
mortality compared to untreated depressed patients (Simon, 
2012).
» Confounding factors (i.e. prior history of self-harm or suicide 
attempts, history of psychiatric hospitalization, comorbid 
personality disorders or substance dependence) may increase 
the risk for developing suicidality, but these are not 
commonly accounted for in studies 
* Few studies include toxicological findings, however, post 
mortem toxicological studies have consistently found that few 
suicide victims have antidepressants in their system at the 
time of their death {Isacsson, Hoigren. & Abler, 2005; Cortes et at., 
2011; Leon et ai., 2004)
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Conclusion
► Genetic factors, such as decreased levels of BDNF, may 
also contribute to suicidal ideation in patients
* There is evidence to support that suicidality is increased 
in the initial four weeks following treatment, but that 
the risk decreases significantly after that time.
* Overall, antidepressants have been found to have a 
protective effect against suicide
* There is not enough evidence to definitively say that 
antidepressants afone cause suicidality
► Further research is needed to determine if there is any 
correlation between anti-depressants and suicidality
There is a need for further research in the areas of
genetics and toxicological studies
particular attention should be paid to the end point of
all studies performed
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